Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | KCNN2 | Q9H2S1 | 4/20 | 0.39 |
| ▸ | KCNN3 | Q9UGI6 | 4/20 | 0.39 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038059 | 0.91 | NQO2 (0.46) | NQO2MTNR1AMTNR1BMAOATSHR | |
| SCHEMBL7037704 | 0.89 | NQO2 (0.37) | NQO2MTNR1AMTNR1BMAOATSHR | |
| SCHEMBL7037840 | 0.89 | NQO2 (0.37) | NQO2MTNR1AMTNR1BMAOATSHR | |
| SCHEMBL7038086 | 0.87 | NQO2 (0.38) | NQO2MTNR1AMTNR1BTSHRABCB1 | |
| SCHEMBL7040485 | 0.87 | ESR1 (0.39) | NQO2MTNR1AMTNR1BTSHRABCB1 | |
| SCHEMBL7038986 | 0.84 | ABCB1 (0.39) | NQO2MTNR1AMTNR1BABCB1 | |
| SCHEMBL7040666 | 0.83 | HTR2A (0.33) | NQO2MTNR1AMTNR1B | |
| SCHEMBL7037226 | 0.82 | PPARD (0.47) | — | |
| SCHEMBL7037093 | 0.82 | MTNR1A (0.50) | NQO2MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL6377152 | 0.81 | MTNR1A (0.49) | NQO2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0878468-B1 | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL CO (JP) | 2003-03-19 | — | — | EP | claimed |
| EP-0888309-B1 | IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA2 RECEPTORS ACTIVITY | ORION CORP (FI) | 2003-03-19 | — | — | EP | disclosed |
| US-6479530-B2 | SUBSTITUTED 4(5)-(1-INDANYL,-INDANYLMETHYL, INDANYLMETHYLEN), 4(5)-(1-(1,2,3,4-TETRAHYDRONAPHTHYL, -NAPHTHYLMETHYL AND NAPHTHYLMETHYLEN)IMIDAZOLES; HYPOTENSIVE, ISCHEMIC AND ANXIOLYTIC AGENTS; NERVOUS AND MUSCULAR SYSTEM DISORDERS | ORION CORPORATION (FI) | 2002-11-12 | — | — | US | disclosed |
| US-20020007074-A1 | Imidazole derivatives having affinity for alpha2 receptors | KARJALAINEN ARTO (FI) | 2002-01-17 | — | — | US | disclosed |
| US-6313311-B1 | ADRENERGIC STIMULANTS FOR POTENTIATING ANESTHETICS PRIOR TO SURGERY; HYPOTENSIVE AGENTS, ANALGESICS, ANTIISCHEMIC AGENTS; NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS | ORION CORPORATION (FI) | 2001-11-06 | — | — | US | disclosed |
| EP-0888309-A1 | IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA2 RECEPTORS ACTIVITY | ORION CORPORATION (FI) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997012874-A1 | IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA2 RECEPTORS ACTIVITY | Orion-Yhtymä Oy (FI) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007074-A1 | Imidazole derivatives having affinity for alpha2 receptors | CHRM1, CHRNA1, CNR1 | NQO2 2755/4885MTNR1A 173/4885MTNR1B 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.